New Data from Deloitte
Avoiding Big Failures with Better Phase II Programs
By Trista Morrison
Monday, October 25, 2010
Facing limited venture financing and public offering options, many biotechs remain focused on cost control, seeking the fastest and cheapest way to push their products through Phase II trials and obtain those critical proof-of-concept data that seem to make deep-pocketed partners prick up their ears.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.